A Review of Clinical Outcomes and Safety Profile of Atezolizumab in Non-Small Cell Lung Cancer Patients

Atezolizumab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), has become a critical component in the therapeutic arsenal against non-small cell lung cancer (NSCLC), which accounts for approximately 85% of all lung cancer cases.This antibody works by inhibiting the interaction between PD-L1 and its receptor PD-1 on T-cells, thereby reactivating the immune system to recognize and attack cancer cells.The emergence of atezolizumab as a significant therapeutic option has been marked by its ability to improve survival rates and provide durable responses in patients with advanced and metastatic NSCLC, making it a cornerstone of immunotherapy in this setting.This review provides a comprehensive examination of the clinical outcomes and safety profile of atezolizumab in NSCLC patients.By analyzing data from pivotal clinical trials such as IMpower150, IMpower130, and OAK, as well as real-world studies, this review aims to elucidate the effectiveness of atezolizumab across various treatment lines and patient subgroups, including those with different levels of PD-L1 expression.The review highlights the substantial survival benefits observed with atezolizumab, particularly when used in combination with chemotherapy or as a monotherapy in PD-L1 high-expressing tumors.It also explores the role of atezolizumab in both first-line and secondline settings, offering insights into its versatility as a treatment option.Furthermore, the review delves into the safety profile of atezolizumab, discussing both the common adverse events, such as fatigue, nausea, and decreased appetite, and the more serious immune-related adverse events (irAEs), including pneumonitis, hepatitis, and colitis.By balancing the discussion of efficacy with an in-depth analysis of potential risks, this review provides a critical overview of atezolizumab's role in the evolving treatment landscape of NSCLC, helping to inform clinical decision-making and patient management.